These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20395423)

  • 1. Failure of the Ipsogen MutaScreen kit to detect the JAK2 617V>F mutation in samples with additional rare exon 14 mutations: implications for clinical testing and report of a novel 618C>F mutation in addition to 617V>F.
    Warshawsky I; Mularo F; Hren C; Jakubowski M
    Blood; 2010 Apr; 115(15):3175-6. PubMed ID: 20395423
    [No Abstract]   [Full Text] [Related]  

  • 2. JAK2 V617F "indeterminate" results by MutaScreen can be easily resolved using MutaQuant kits.
    Hoteit RM; Shammaa DM; Mahfouz RA
    Genet Test Mol Biomarkers; 2012 Feb; 16(2):146-9. PubMed ID: 21933004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of the JAK2V617F mutation with the Ipsogen MutaScreen kit: absence of JAK2V617F does not mean absence of myeloproliferative neoplasm.
    Peyro-Saint-Paul H; Hermitte F
    Blood; 2010 Sep; 116(11):1994-5. PubMed ID: 20847214
    [No Abstract]   [Full Text] [Related]  

  • 4. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
    Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
    Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis.
    Jones AV; Cross NC; White HE; Green AR; Scott LM
    Haematologica; 2008 Oct; 93(10):1560-4. PubMed ID: 18698085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation.
    Passamonti F; Randi ML; Rumi E; Pungolino E; Elena C; Pietra D; Scapin M; Arcaini L; Tezza F; Moratti R; Pascutto C; Fabris F; Morra E; Cazzola M; Lazzarino M
    Blood; 2007 Jul; 110(2):485-9. PubMed ID: 17426257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
    Vannucchi AM; Antonioli E; Guglielmelli P; Rambaldi A; Barosi G; Marchioli R; Marfisi RM; Finazzi G; Guerini V; Fabris F; Randi ML; De Stefano V; Caberlon S; Tafuri A; Ruggeri M; Specchia G; Liso V; Rossi E; Pogliani E; Gugliotta L; Bosi A; Barbui T
    Blood; 2007 Aug; 110(3):840-6. PubMed ID: 17379742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 V617F mutation detection: laboratory comparison of two kits using RFLP and qPCR.
    Shammaa D; Bazarbachi A; Halas H; Greige L; Mahfouz R
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):13-5. PubMed ID: 19877761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods for detecting mutations in the human JAK2 gene.
    Bench AJ; Baxter EJ; Green AR
    Methods Mol Biol; 2013; 967():115-31. PubMed ID: 23296725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis.
    Ohyashiki JH; Hisatomi H; Shimizu S; Sugaya M; Ohyashiki K
    Jpn J Clin Oncol; 2009 Aug; 39(8):509-13. PubMed ID: 19491085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.
    Dupont S; Massé A; James C; Teyssandier I; Lécluse Y; Larbret F; Ugo V; Saulnier P; Koscielny S; Le Couédic JP; Casadevall N; Vainchenker W; Delhommeau F
    Blood; 2007 Aug; 110(3):1013-21. PubMed ID: 17389763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent 'JAK2-negative' polycythaemia vera due to compound mutations in exon 14.
    Tiong IS; Casolari DA; Moore S; Nguyen T; Van Velzen MJM; Zantomio D; Scott HS; D'Andrea RJ; Hahn CN; Ross DM
    Br J Haematol; 2017 Jul; 178(2):333-336. PubMed ID: 27136492
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel JAK2 exon 12 mutation identified in the retrospective analysis of paraffin-embedded tissues of polycythemia vera patients.
    Burjanivova T; Marcinek J; Lasabova Z; Minarik G; Szepe P; Balharek T; Vanochova A; Polacek H; Plank L
    Diagn Mol Pathol; 2009 Jun; 18(2):108-11. PubMed ID: 19430293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
    Pietra D; Li S; Brisci A; Passamonti F; Rumi E; Theocharides A; Ferrari M; Gisslinger H; Kralovics R; Cremonesi L; Skoda R; Cazzola M
    Blood; 2008 Feb; 111(3):1686-9. PubMed ID: 17984312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
    Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
    Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis.
    Albiero E; Madeo D; Ruggeri M; Bernardi M; Giorgetti A; Rodeghiero F
    Br J Haematol; 2008 Sep; 142(6):986-90. PubMed ID: 18671703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.
    Li S; Kralovics R; De Libero G; Theocharides A; Gisslinger H; Skoda RC
    Blood; 2008 Apr; 111(7):3863-6. PubMed ID: 18195094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels.
    Percy MJ; Scott LM; Erber WN; Harrison CN; Reilly JT; Jones FG; Green AR; McMullin MF
    Haematologica; 2007 Dec; 92(12):1607-14. PubMed ID: 18055983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative bead-based assay for detection of JAK2 exon 12 mutations.
    Shivarov V; Ivanova M; Yaneva S; Petkova N; Hadjiev E; Naumova E
    Leuk Lymphoma; 2013 Jun; 54(6):1343-4. PubMed ID: 23121686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.